Neovasc Inc. Keeps Picking up Steam

Neovasc Inc. (TSX:NVC)(NASDAQ:NVCN) sold off some of its assets and released data regarding one of its products. The company is in a good spot moving forward.

| More on:
The Motley Fool

Neovasc Inc. (TSX:NVC)(NASDAQ:NVCN) is among Canada’s leaders in the medical equipment industry, and the British Columbia–based corporation’s recent moves put its shareholders in a good position moving forward.

Boston Scientific Corporation (NYSE:BSX) completed a transaction with Neovasc. The former will acquire part of Neovasc’s business, including its advanced biologic tissue segment as well as some manufacturing assets. The deal is worth US$75 million in cash, and it will also net Boston Scientific a 15% stake in the company.

The deal will give Neovasc a license to the assets and facilities that are being sold, allowing the company to proceed with the research and development of some of its projects. Its tissue and valve equipment will remain in development at these locations, including its mitral bioprosthesis valve Tiara.

The company also offered an update on what is happening with its Tiara transcatheter mitral valve, which treats mitral regurgitation. Twenty-two patients have received Tiara valve treatments in Canada, the U.S., and Europe. Neovasc patients have experienced an 86% success rate, amounting to 19 patients reacting positively to the treatment.

What success means within this context is a considerably improved function of the patient’s condition with one patient surviving three years with the implant, which is still functioning at its highest capacity. No negative effects related to the Tiara implants have been reported in any of the patients that were treated and followed up with.

A new treatment has been approved that will examine Tiara’s safety and performance. There will be 115 patients involved in the Italian study, which will accrue data that will be used to file for the product’s approval with the CE Mark, the regulatory agency in the European Union. TIARA II will begin in the first quarter of 2017.

Going back to the Neovasc deal with Boston Scientific, the latter has bought more than 11.8 million common shares of the company. Boston Scientific is paying 60 cents per share, tallying up to $7.09 million. Neovasc will use these funds to iron out a legal situation the company is dealing with as well as for general corporate purposes.

Neovasc has a market capitalization of $197.22 million. Analysts polled by Zacks Investment Research rate Neovasc a two on a one to five scale. A two represents a “Buy.” Most analysts rate it a two. Shares fell 1.1% Thursday afternoon, lowering the stock’s price to $2.75 per share.

The medical equipment market in Canada has a bright future ahead; most companies are based in Ontario, Quebec, and British Columbia. The industry was worth $6 billion in sales last year, and this figure is expected to rise moving forward.

Neovasc also has a presence in the U.S., where the medical equipment industry has a bright future as well. The market value of the industry comes in at about $148 billion with this figure expected to rise to $155 billion in 2017.

Now is a good time to invest in Neovasc, which has some very promising projects in the horizon. Additionally, the Boston Scientific deal will help it solidify its portfolio. Watch out for this stock next year.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karl Utermohlen has no position in any stocks mentioned.

More on Investing

Train cars pass over trestle bridge in the mountains
Dividend Stocks

Is CNR Stock a Buy, Sell, or Hold for 2025?

Can CNR stock continue its long-term outperformance into 2025 and beyond? Let's explore whether now is a good time to…

Read more »

engineer at wind farm
Energy Stocks

Invest $20,000 in This Dividend Stock for $100 in Monthly Passive Income

This dividend stock has it all – a strong outlook, monthly income, and even more to consider buying today.

Read more »

Hourglass and stock price chart
Stock Market

It’s Not Too Late: Invest in These TSX Growth Stocks Now

Solid fundamentals of these top TSX growth stocks could help them maintain strong upward momentum in the years to come.

Read more »

coins jump into piggy bank
Dividend Stocks

The Smartest Dividend Stocks to Buy With $500 Right Now

These top dividend stocks both offer attractive yields and trade off their highs, making them two of the best to…

Read more »

stocks climbing green bull market
Stocks for Beginners

3 TSX Stocks Soaring Higher With No Signs of Slowing

Don't ignore stocks just because they look like they're at a high price. Instead, see exactly why they've driven so…

Read more »

dividends can compound over time
Bank Stocks

Is TD Bank Stock a Buy for Its 5.2% Dividend Yield?

TD Bank stock offers a rare 5.2% dividend yield—can it rebound from challenges and reward contrarian investors? Here's what to…

Read more »

chart reflected in eyeglass lenses
Investing

How Should a Beginner Invest in Stocks? Start With This Index Fund

This Vanguard index fund is the perfect way to start a Canadian investment portfolio.

Read more »

analyze data
Bank Stocks

Is BMO Stock a Buy for its 4.7% Dividend Yield?

Bank of Montreal is up 20% since late August. Are more gains on the way?

Read more »